Time to symptom elimination is a statistically inefficient endpoint for respiratory virus trials that ignores the most clinically relevant timepoints. Alternatively, clearance slope and area under the curve may efficiently capture improvement early during treatment when symptoms are most severe.
Schiffer et al. (Wed,) studied this question.